Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Small Business Research Grants Reauthorized Under The Wire

Executive Summary

Congress extended the Small Business Innovation Research and Small Business Technology Transfer programs, right before they were set to expire on 30 September.

You may also be interested in...



Dire Warning From Small-Business Grant Recipient: End Of Program Will ‘Kill’ Medtech Jobs, Companies

The CEO of a medtech firm that has received multiple innovation grants from the US government says small companies like hers would be endangered if the funding disappears.

CDS Final Guidance Draws More Criticism, This Time From Congress

Senator Bill Cassidy says FDA “disregarded” Congressional intent by expanding its authority to regulate clinical decision support software.

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

AdvaMed’s new online clock documents the time since CMS promised to replace MCIT, a program guaranteeing coverage for FDA-cleared breakthrough devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel